Can circumcision be avoided in adult male with phimosis? Results of the PhimoStop

Kikiros grade Phimosis adult male phimosis circumcision non-surgical treatment of phimosis

Journal

Translational andrology and urology
ISSN: 2223-4691
Titre abrégé: Transl Androl Urol
Pays: China
ID NLM: 101581119

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 30 07 2021
accepted: 04 10 2021
entrez: 5 1 2022
pubmed: 6 1 2022
medline: 6 1 2022
Statut: ppublish

Résumé

Circumcision as surgical treatment of adult phimosis is not devoid of complications. Efficacy of alternative non-surgical options is unclear. PhimoStop A prospective trial was conducted between 2018 and 2020 on 85 consecutive adult male patients affected by phimosis and with an indication for circumcision. Patients were treated with PhimoStop Seventy-one patients (84%) completed the device usage phase as per study protocol. Median duration of tuboid application was 60 days. Thirty-seven patients (52.1%) had no indication for circumcision after treatment. Even considering patients lost to follow-up as failures, primary endpoint was reached in 43.5% of cases. There was a significant reduction of the grade of phimosis after treatment (P<0.001). Moreover IIEF-5 showed a statistically significant improvement after treatment (P<0.001). Thirty/37 patients who met the primary endpoint (81%) still have a successful resolution of their phimosis avoiding circumcision at a median follow-up of 24 months. PhimoStop

Sections du résumé

BACKGROUND BACKGROUND
Circumcision as surgical treatment of adult phimosis is not devoid of complications. Efficacy of alternative non-surgical options is unclear. PhimoStop
METHODS METHODS
A prospective trial was conducted between 2018 and 2020 on 85 consecutive adult male patients affected by phimosis and with an indication for circumcision. Patients were treated with PhimoStop
RESULTS RESULTS
Seventy-one patients (84%) completed the device usage phase as per study protocol. Median duration of tuboid application was 60 days. Thirty-seven patients (52.1%) had no indication for circumcision after treatment. Even considering patients lost to follow-up as failures, primary endpoint was reached in 43.5% of cases. There was a significant reduction of the grade of phimosis after treatment (P<0.001). Moreover IIEF-5 showed a statistically significant improvement after treatment (P<0.001). Thirty/37 patients who met the primary endpoint (81%) still have a successful resolution of their phimosis avoiding circumcision at a median follow-up of 24 months.
CONCLUSIONS CONCLUSIONS
PhimoStop

Identifiants

pubmed: 34984181
doi: 10.21037/tau-21-673
pii: tau-10-11-4152
pmc: PMC8661253
doi:

Types de publication

Journal Article

Langues

eng

Pagination

4152-4160

Informations de copyright

2021 Translational Andrology and Urology. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/tau-21-673). The authors have no conflicts of interest to declare.

Références

Urol Int. 2015;94(3):255-61
pubmed: 25677813
Cochrane Database Syst Rev. 2021 Mar 31;3:CD012250
pubmed: 33786810
Int Urol Nephrol. 2016 Mar;48(3):335-42
pubmed: 26725071
Urology. 2021 Feb;148:274-279
pubmed: 33248142
Cochrane Database Syst Rev. 2014 Sep 02;(9):CD008973
pubmed: 25180668
Urology. 2021 Jun;152:25-34
pubmed: 33545206
Am Fam Physician. 1999 Mar 15;59(6):1514-8
pubmed: 10193593
ScientificWorldJournal. 2011;11:2458-68
pubmed: 22235177
PLoS One. 2018 Mar 26;13(3):e0194271
pubmed: 29579082
J Surg Tech Case Rep. 2013 Jan;5(1):1-7
pubmed: 24470842
ISRN Urol. 2012;2012:707329
pubmed: 23002427
J Sex Med. 2017 Apr;14(4):601-612
pubmed: 28364982
J Sex Med. 2007 Nov;4(6):1626-34
pubmed: 17888069
Int J Impot Res. 1999 Dec;11(6):319-26
pubmed: 10637462
J Sex Med. 2013 Jun;10(6):1516-25
pubmed: 23551571
Sex Med. 2021 Apr;9(2):100315
pubmed: 33545503

Auteurs

Marco Carilli (M)

Division of Urology, Fondazione PTV Policlinico Tor Vergata, Rome, Italy.

Anastasios D Asimakopoulos (AD)

Division of Urology, Fondazione PTV Policlinico Tor Vergata, Rome, Italy.

Serena Pastore (S)

Division of Urology, Fondazione PTV Policlinico Tor Vergata, Rome, Italy.

Stefano Germani (S)

Division of Urology, Fondazione PTV Policlinico Tor Vergata, Rome, Italy.

Luca Orecchia (L)

Division of Urology, Fondazione PTV Policlinico Tor Vergata, Rome, Italy.

Enrico Finazzi Agrò (EF)

Department of Surgical Sciences, Division of Urology, University of Rome Tor Vergata, Rome, Italy.

Roberto Miano (R)

Department of Surgical Sciences, Division of Urology, University of Rome Tor Vergata, Rome, Italy.

Classifications MeSH